1.60
5.26%
0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.52
Aprire:
$1.55
Volume 24 ore:
610.37K
Relative Volume:
1.98
Capitalizzazione di mercato:
$143.31M
Reddito:
-
Utile/perdita netta:
$-93.61M
Rapporto P/E:
-0.4665
EPS:
-3.43
Flusso di cassa netto:
$-71.16M
1 W Prestazione:
+14.29%
1M Prestazione:
+21.21%
6M Prestazione:
+22.14%
1 anno Prestazione:
+11.89%
Immunic Inc Stock (IMUX) Company Profile
Nome
Immunic Inc
Settore
Industria
Telefono
(332) 255-9818
Indirizzo
1200 AVENUE OF THE AMERICAS, NEW YORK
Immunic Inc Stock (IMUX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2022-09-19 | Ripresa | H.C. Wainwright | Buy |
2021-04-15 | Iniziato | Aegis Capital | Buy |
2021-03-24 | Iniziato | JMP Securities | Mkt Outperform |
2020-10-02 | Iniziato | SVB Leerink | Outperform |
2020-08-26 | Iniziato | Piper Sandler | Overweight |
2020-08-07 | Ripresa | ROTH Capital | Buy |
2020-07-20 | Iniziato | BMO Capital Markets | Outperform |
2020-06-05 | Iniziato | Wedbush | Outperform |
2020-05-11 | Iniziato | H.C. Wainwright | Buy |
2020-03-25 | Iniziato | ROTH Capital | Buy |
2019-07-11 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Immunic Inc Borsa (IMUX) Ultime notizie
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies - Proactive Investors UK
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies - Proactive Investors USA
Immunic, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.22) Per Share (NASDAQ:IMUX) - Defense World
Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX), - Yahoo Finance
Research Analysts Offer Predictions for Immunic, Inc.'s Q3 2024 Earnings (NASDAQ:IMUX) - MarketBeat
Leerink Partnrs Upgrades Immunic (NASDAQ:IMUX) to Strong-Buy - Defense World
Immunic (NASDAQ:IMUX) Upgraded by Leerink Partnrs to "Strong-Buy" - MarketBeat
Immunic’s (IMUX) Outperform Rating Reaffirmed at Leerink Partners - Defense World
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com Australia
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com India
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com Canada
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com UK
Immunic, Inc. (NASDAQ:IMUX) Receives $12.75 Consensus Target Price from Analysts - MarketBeat
Immunic (NASDAQ:IMUX) Receives Outperform Rating from Leerink Partners - MarketBeat
Immunic drug targeting post-COVID syndrome in Phase 2 trialICYMI - Proactive financial news
Immunic Welcomes Jason Tardio As COO And President - Contract Pharma
Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors Australia
Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors USA
Immunic shares hold steady price target, overweight on MS program potential - Investing.com
Immunic shares hold steady price target, overweight on MS program potential - Investing.com India
Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors USA
EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - sharewise
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - PR Newswire
Immunic extends Executive Chairman's term, raises salary - Investing.com
Immunic extends Executive Chairman's term, raises salary By Investing.com - Investing.com Canada
Immunic extends Executive Chairman's term, raises salary By Investing.com - Investing.com UK
Immunic, Inc. (NASDAQ:IMUX) Short Interest Down 6.3% in August - MarketBeat
There is no doubt that Immunic Inc (IMUX) ticks all the boxes. - SETE News
Immunic Inc (IMUX) shows promising results - US Post News
Immunic, Inc. (NASDAQ:IMUX) Sees Large Decrease in Short Interest - Defense World
Immunic, Inc. (NASDAQ:IMUX) to Post Q3 2024 Earnings of ($0.23) Per Share, B. Riley Forecasts - MarketBeat
Immunic to highlight lead asset’s promise at upcoming Multiple Sclerosis R&D Day - Proactive Investors UK
Market Resilience: Immunic Inc (IMUX) Finishes Weak at 1.40, Down -3.10 - The Dwinnex
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September - StockTitan
Immunic initiated with a Buy at B. Riley - TipRanks
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September - Yahoo Finance
B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential - Investing.com
Immunic (NASDAQ:IMUX) Now Covered by B. Riley - Defense World
B. Riley Initiates Coverage on Immunic (NASDAQ:IMUX) - MarketBeat
B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential - Investing.com India
Immunic Inc (IMUX) Stock: A Year of Market Fluctuations - The InvestChronicle
Immunic Stock (NASDAQ:IMUX): CEO Says “Right Time to Buy Now” - TipRanks
Immunic, Inc. (NASDAQ:IMUX) Short Interest Down 8.8% in July - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Shares Purchased by Vanguard Group Inc. - MarketBeat
Vanguard Group Inc. Buys 1,703,047 Shares of Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic, Inc.'s (NASDAQ:IMUX) Shift From Loss To Profit - Simply Wall St
Biotech Alert: Searches spiking for these stocks today - TipRanks
Immunic (NASDAQ:IMUX) Rating Increased to Hold at StockNews.com - MarketBeat
StockNews.com Upgrades Immunic (NASDAQ:IMUX) to Hold - Defense World
Multiple Sclerosis Pipeline Drugs 2024 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, Ge - Barchart
Immunic Inc Azioni (IMUX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):